All Title Author
Keywords Abstract

PLOS ONE  2013 

Soluble Isoform of the Receptor for Advanced Glycation End Products as a Biomarker for Postoperative Respiratory Failure after Cardiac Surgery

DOI: 10.1371/journal.pone.0070200

Full-Text   Cite this paper   Add to My Lib

Abstract:

Purpose Postoperative respiratory failure is a major problem which can prolong the stay in the intensive care unit in patients undergoing cardiac surgery. We measured the serum levels of the soluble isoform of the receptor for advanced glycation end products (sRAGE), and we studied its association with postoperative respiratory failure. Methods Eighty-seven patients undergoing elective cardiac surgery were enrolled in this multicenter observational study in three university hospitals. Serum biomarker levels were measured perioperatively, and clinical data were collected for 7 days postoperatively. The duration of mechanical ventilation was studied for 28 days. Results Serum levels of sRAGE elevated immediately after surgery (median, 1751 pg/mL; interquartile range (IQR) 1080–3034 pg/mL) compared with the level after anesthetic induction (median, 884 pg/mL; IQR, 568–1462 pg/mL). Postoperative sRAGE levels in patients undergoing off-pump coronary artery bypass grafting (median, 1193 pg/mL; IQR 737–1869 pg/mL) were significantly lower than in patients undergoing aortic surgery (median, 1883 pg/mL; IQR, 1406–4456 pg/mL; p = 0.0024) and valve surgery (median, 2302 pg/mL; IQR, 1447–3585 pg/mL; p = 0.0005), and postoperative sRAGE correlated moderately with duration of cardiopulmonary bypass (rs = 0.44, p<0.0001). Receiver operating characteristic curve analysis demonstrated that postoperative sRAGE had a predictive performance with area under the curve of 0.81 (95% confidence interval 0.71–0.88) for postoperative respiratory failure, defined as prolonged mechanical ventilation >3 days. The optimum cutoff value for prediction of respiratory failure was 3656 pg/mL, with sensitivity and specificity of 62% and 91%, respectively. Conclusions Serum sRAGE levels elevated immediately after cardiac surgery, and the range of elevation was associated with the morbidity of postoperative respiratory failure. Early postoperative sRAGE levels appear to be linked to cardiopulmonary bypass, and may have predictive performance for postoperative respiratory failure; however, large-scale validation studies are needed.

References

[1]  Paparella D, Yau TM, Young E (2002) Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg 21: 232–244.
[2]  Ranieri VM, Vitale N, Grasso S, Puntillo F, Mascia L, et al. (1999) Time-course of impairment of respiratory mechanics after cardiac surgery and cardiopulmonary bypass. Crit Care Med 27: 1454–1460.
[3]  Filsoufi F, Rahmanian PB, Castillo JG, Chikwe J, Adams DH (2008) Predictors and early and late outcomes of respiratory failure in contemporary cardiac surgery. Chest 133: 713–721.
[4]  Reddy SL, Grayson AD, Griffiths EM, Pullan DM, Rashid A (2007) Logistic risk model for prolonged ventilation after adult cardiac surgery. Ann Thorac Surg 84: 528–536.
[5]  Pappalardo F, Franco A, Landoni G, Cardano P, Zangrillo A, et al. (2004) Long-term outcome and quality of life of patients requiring prolonged mechanical ventilation after cardiac surgery. Eur J Cardiothorac Surg 25: 548–552.
[6]  Canver CC, Chanda J (2003) Intraoperative and postoperative risk factors for respiratory failure after coronary bypass. Ann Thorac Surg 75: 853–857; discussion 857–858.
[7]  Spivack SD, Shinozaki T, Albertini JJ, Deane R (1996) Preoperative prediction of postoperative respiratory outcome. Coronary artery bypass grafting. Chest 109: 1222–1230.
[8]  Cohen AJ, Katz MG, Frenkel G, Medalion B, Geva D, et al. (2000) Morbid results of prolonged intubation after coronary artery bypass surgery. Chest 118: 1724–1731.
[9]  Serrano N, Garcia C, Villegas J, Huidobro S, Henry CC, et al. (2005) Prolonged intubation rates after coronary artery bypass surgery and ICU risk stratification score. Chest 128: 595–601.
[10]  Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, et al. (1993) Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143: 1699–1712.
[11]  Shirasawa M, Fujiwara N, Hirabayashi S, Ohno H, Iida J, et al. (2004) Receptor for advanced glycation end-products is a marker of type I lung alveolar cells. Genes Cells 9: 165–174.
[12]  Uchida T, Shirasawa M, Ware LB, Kojima K, Hata Y, et al. (2006) Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med 173: 1008–1015.
[13]  Pelaez A, Force SD, Gal AA, Neujahr DC, Ramirez AM, et al. (2010) Receptor for advanced glycation end products in donor lungs is associated with primary graft dysfunction after lung transplantation. American Journal of Transplantation 10: 900–907.
[14]  Calfee CS, Budev MM, Matthay MA, Church G, Brady S, et al. (2007) Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation. J Heart Lung Transplant 26: 675–680.
[15]  Christie JD, Shah CV, Kawut SM, Mangalmurti N, Lederer DJ, et al. (2009) Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med 180: 1010–1015.
[16]  Bopp C, Hofer S, Weitz J, Bierhaus A, Nawroth PP, et al. (2008) sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 147: 79–83.
[17]  Soop A, Sunden-Cullberg J, Albert J, Hallstrom L, Treutiger CJ, et al. (2009) Adenosine infusion attenuates soluble RAGE in endotoxin-induced inflammation in human volunteers. Acta Physiol (Oxf) 197: 47–53.
[18]  Hubbard AR, Rigsby P, Barrowcliffe TW (2001) Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586). Thromb Haemost 85: 634–638.
[19]  Murray JF, Matthay MA, Luce JM, Flick MR (1988) An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 138: 720–723.
[20]  Fluss R, Faraggi D, Reiser B (2005) Estimation of the Youden Index and its Associated Cutoff Point. Biometrical Journal 47: 458–472.
[21]  Akobeng AK (2007) Understanding diagnostic tests 3: receiver operating characteristic curves. Acta P?diatrica 96: 644–647.
[22]  Briot R, Frank JA, Uchida T, Lee JW, Calfee CS, et al. (2009) Elevated levels of the receptor for advanced glycation end products, a marker of alveolar epithelial type I cell injury, predict impaired alveolar fluid clearance in isolated perfused human lungs. Chest 135: 269–275.
[23]  Frank JA, Briot R, Lee JW, Ishizaka A, Uchida T, et al. (2007) Physiological and biochemical markers of alveolar epithelial barrier dysfunction in perfused human lungs. American Journal of Physiology-Lung Cellular and Molecular Physiology 293: L52–L59.
[24]  Guo WA, Knight PR, Raghavendran K (2012) The receptor for advanced glycation end products and acute lung injury/acute respiratory distress syndrome. Intensive Care Med: doi: ––10.1007/s00134–00012–02624-y.
[25]  Fremont RD, Koyama T, Calfee CS, Wu W, Dossett LA, et al. (2010) Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis. J Trauma 68: 1121–1127.
[26]  Calfee CS, Ware LB, Eisner MD, Parsons PE, Thompson BT, et al. (2008) Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 63: 1083–1089.
[27]  Hanford LE, Enghild JJ, Valnickova Z, Petersen SV, Schaefer LM, et al. (2004) Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 279: 50019–50024.
[28]  Yamakawa N, Uchida T, Matthay MA, Makita K (2011) Proteolytic release of the receptor for advanced glycation end products from in vitro and in situ alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 300: L516–525.
[29]  Gasparovic H, Plestina S, Sutlic Z, Husedzinovic I, Coric V, et al. (2007) Pulmonary lactate release following cardiopulmonary bypass. Eur J Cardiothorac Surg 32: 882–887.
[30]  Apostolakis E, Filos KS, Koletsis E, Dougenis D (2010) Lung dysfunction following cardiopulmonary bypass. J Card Surg 25: 47–55.
[31]  Agostoni P, Banfi C, Brioschi M, Magri D, Sciomer S, et al. (2011) Surfactant protein B and RAGE increases in the plasma during cardiopulmonary bypass: a pilot study. Eur Respir J 37: 841–847.
[32]  Bajwa EK, Januzzi JL, Gong MN, Thompson BT, Christiani DC (2008) Prognostic value of plasma N-terminal probrain natriuretic peptide levels in the acute respiratory distress syndrome. Crit Care Med 36: 2322–2327.
[33]  Li G, Daniels CE, Kojicic M, Krpata T, Wilson GA, et al. (2009) The accuracy of natriuretic peptides (brain natriuretic peptide and N-terminal pro-brain natriuretic) in the differentiation between transfusion-related acute lung injury and transfusion-related circulatory overload in the critically ill. Transfusion 49: 13–20.
[34]  Wang LJ, Lu L, Zhang FR, Chen QJ, De Caterina R, et al. (2011) Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. Eur J Heart Fail 13: 440–449.
[35]  Raposeiras-Roubin S, Rodino-Janeiro BK, Grigorian-Shamagian L, Moure-Gonzalez M, Seoane-Blanco A, et al. (2010) Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE. Eur J Heart Fail 12: 1092–1100.
[36]  Agostoni P, Banfi C, Magri D, Vignati C, Doria E, et al. (2011) Kinetics of plasma SPB and RAGE during mechanical ventilation in patients undergoing major vascular surgery. Respir Physiol Neurobiol 178: 256–260.
[37]  Basta G (2008) Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 196: 9–21.
[38]  Jabaudon M, Futier E, Roszyk L, Chalus E, Guerin R, et al. (2011) Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients. Crit Care Med 39: 480–488.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

微信:OALib Journal